EP Wealth Advisors LLC Has $46.50 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

EP Wealth Advisors LLC grew its position in shares of CVS Health Co. (NYSE:CVS) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 588,908 shares of the pharmacy operator’s stock after acquiring an additional 25,001 shares during the quarter. EP Wealth Advisors LLC’s holdings in CVS Health were worth $46,500,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Atticus Wealth Management LLC raised its stake in shares of CVS Health by 149.0% during the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after purchasing an additional 219 shares in the last quarter. USA Financial Formulas raised its stake in CVS Health by 573.2% in the 4th quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after acquiring an additional 321 shares during the period. ZRC Wealth Management LLC raised its stake in CVS Health by 400.0% in the 4th quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after acquiring an additional 400 shares during the period. Coston McIsaac & Partners increased its position in CVS Health by 42.6% during the 4th quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock worth $42,000 after buying an additional 161 shares during the period. Finally, Northwest Financial Advisors bought a new position in CVS Health during the 4th quarter worth $42,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig purchased 1,000 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was acquired at an average price of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.24% of the stock is currently owned by corporate insiders.

CVS Health Trading Down 1.3 %

Shares of CVS stock traded down $0.81 during trading hours on Friday, reaching $60.22. The company’s stock had a trading volume of 11,690,758 shares, compared to its average volume of 12,659,378. The firm’s fifty day simple moving average is $61.51 and its 200 day simple moving average is $70.92. The stock has a market capitalization of $75.60 billion, a P/E ratio of 10.58, a P/E/G ratio of 0.57 and a beta of 0.53. CVS Health Co. has a one year low of $52.77 and a one year high of $83.25. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The company had revenue of $88.44 billion for the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.20 EPS. Equities research analysts expect that CVS Health Co. will post 7.02 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Monday, April 22nd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.42%. The ex-dividend date of this dividend was Friday, April 19th. CVS Health’s payout ratio is currently 46.75%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CVS. Robert W. Baird assumed coverage on CVS Health in a report on Thursday, May 30th. They set a “neutral” rating and a $61.00 target price on the stock. Truist Financial restated a “buy” rating and set a $66.00 price objective (down from $90.00) on shares of CVS Health in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $58.00 target price on shares of CVS Health in a report on Wednesday. Piper Sandler lifted their target price on CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Baird R W raised CVS Health to a “hold” rating in a research report on Thursday, May 30th. Eleven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $75.05.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.